Although these drugs are not recognized as treatment options for NDDs, the similarity of EZH1 GOF variants with those found in EZH2 associated cancers suggest a potential route for epigenetic recovery of EZH1 GOF using EZH1/2 inhibitors. Here, EZH1 is linked to cancer.